Skip to content

Effectiveness of Screening and Brief Interventions for Alcohol and Tobacco During Breast Cancer Treatment (ONKODETOX)

Effectiveness of Screening and Brief Interventions for Alcohol and/or Tobacco During Breast Cancer Treatment: A Phase III, Pilot Prospective Randomized Trial (ONKODETOX)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03371732
Acronym
ONKODETOX
Enrollment
104
Registered
2017-12-13
Start date
2016-03-31
Completion date
2019-04-30
Last updated
2022-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Psychology, Social

Keywords

Psychological intervention Alcohol, Tobacco consumption, Substance use, Health risk behavior, Oncology setting, Women, Supportive care

Brief summary

Despite scientific, clinical and political incentives, alcohol and/or tobacco screening and brief intervention (SBI) services are poorly implemented in oncology settings. Motivational brief interventions are recognized as particularly effective in changing health behaviors, especially consumption behaviors. The motivational approach is more and more used in primary care setting but still few studies explore its effectiveness with breast cancer patients. This study aims to compare two intervention arms : educational advices intervention (EAI) versus brief motivational intervention (BMI) for alcohol and/or tobacco consumption in breast cancer women, during their treatment. In this pilot prospective randomized trial, various psychological and behavioral, variables are measured (alcohol and tobacco consumption, distress, anxiety and depressive disorders, quality of life, motivation for change, empowerment) before the brief intervention, and after 3 and 6 month.

Detailed description

Context : It is now well documented that alcohol and tobacco reduce the effectiveness of a treatment, increase the side effects, favor the recurrence and/or secondary cancers and affects the quality of life of patients treated for cancer, including breast cancer. The announcement of the disease could create a window of opportunity for change in lifestyle for patients. The 2014-2019 French Cancer Plan emphasizes the need for the implementation of prevention and risk reduction related to alcohol and tobacco. A screening, brief motivational and referral to treatment program, specifically dedicated to oncology can be public health approach aiming to reduce the harmful consequences of substance misuse and improving the prognosis and quality of life of consumers at risk. Main objective : Evaluate effectiveness of a brief motivational intervention for alcohol and/or tobacco in short (3 month) and medium (6 month) terms in breast cancer patients, in a prospective randomized pilot study. Secondary objectives : * Determine the behavioral and psychopathological specific characteristics of the patient linked to change process and maintain. * Define a brief intervention for alcohol/tobacco consumption model adapted and integrated to patient treated for cancer according to psychosocial factors highlighted. The investigators will seek to highlight the benefit of a motivational brief intervention versus standardized educational advice. The specificity of these interventions is to be integrated in an interview integrating a systematic screening of the emotional distress of the patient, of these concerns as well as of his perceived need for aids. Method : This is a randomized clinical trial comparing two interventions. The trial includes 200 primary breast cancer patients with a positive AUDIT-C score and/or are tobacco consumers, randomly placed in two groups : G1 : Motivational Intervention group (N = 100) : Participants in the intervention group benefit a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention. G2 : Educational advises group (N = 100) : Participants in this group benefit of brief educational advises (10 minutes interview maximum), and received a pamphlet on the health effects of alcohol and tobacco consumption. For obvious ethical reasons, the investigators selected an intervention in the form of advice concerning the effects of the product and the submission of specific documentation (criteria not retained in the context of the brief intervention model). It did not seem possible to evaluate patients without offering them the possibility of a low threshold intervention. Detailed scripts for each modality of intervention are realized. Measurement : Three sets of measurements are taken at baseline, 3-month and 6 month follow-up. Primary Outcome measures: Clinically significant reduction (beneficial to health) of risk behaviours (alcohol and/or tobacco consumption) : * Concerning subjects with only alcohol consumption at baseline : The intervention will be considered effective at 3 months if an individual decrease of 20% in the AUDIT score is observed at 3 months compared to the value collected at baseline; The intervention will be considered effective at 6 months if this 20% reduction is maintained at 6 months, still in relation to the value collected at baseline. * The same applies to subjects with only tobacco consumption at baseline: The intervention will be considered effective at 3 months if an individual decrease of 20% in the number of cigarettes consumed per day is observed at 3 months compared to the value collected at baseline; The intervention will be judged effective at 6 months if this 20% reduction is maintained at 6 months, still in relation to the value collected at baseline. * Finally, with regard to women with both alcohol and tobacco use at baseline : The intervention will be considered effective if at least one of the two scores (AUDIT or number of cigarettes consumed per day) has decreased by 20% at 3 months (maintained at 6 months) compared to the value collected at baseline, with no increase in the other score. Secondary outcome measures : * Individual reduction of around 20% in average daily consumption of alcohol and/or tobacco (calculated on the basis of patients' consumption schedules) between inclusion and the first follow-up at 3 months, and maintenance of this success at the second follow-up at 6 months (with no increase in other consumption if the subject has both alcohol and tobacco consumption at inclusion); * Description of the variables relating to the consumption of alcohol, tobacco, the current medico-psychological situation, psychological distress, anxio-depressive symptomatology, willingness to change alcohol and/or tobacco consumption habits; * Improved quality of life in the experimental intervention arm compared to the standard intervention arm Study procedure : SCREENING-PRE-INCLUSION: Screening of distress and alcohol/tobacco consumptions is realized when the patients arrive in the oncology department for their chemotherapy treatment, by a research assistant-psychologist. Researchers propose to eligible patients to participate to the study. This first contact permits to check the absence of non-inclusion criteria; to ensure the informed consent of the person (an information and consent note will be given to him) and according to these elements, to define the provisional timetable for participation in the research. T0 - INCLUSION AND RANDOMIZATION The research assistant retrieves the signed consent, ensuring a time available to return if necessary and carries out the research interview/assessment. The randomization is realized following this interview. INTERVENTION: Brief intervention (G1 : Brief motivational intervention or G2 : educational advices) are conducted by the research assistant-psychologist, at the Institut Bergonié or by telephone if needed. T1: MONITORING - FOLLOW-UP(3 months) Assessments are repeated, when the patient comes at the Institut Bergonié, by telephone if necessary. T2: MONITORING - FOLLOW-UP (6 months) Assessments are repeated, when the patient comes at the Institut Bergonié, by telephone if necessary. Randomization procedure : The randomization procedure is done via the TENALEA server, managed by the Epidemiological and Clinical Research Unit (UREC) of the Bergonié Institute. Expected results : Highlighting: * The efficacy of motivational brief intervention on alcohol and tobacco consumption in patients treated for breast cancer ; versus educational advices intervention. * Psychosocial risk factors involved in maintaining problematic consumption or in the rapid relapse of tobacco/alcohol consumption.

Interventions

BEHAVIORALMotivational Intervention group

Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.

BEHAVIORALEducational advises group

Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.

Sponsors

Ligue contre le cancer, France
CollaboratorOTHER
Institut Bergonié
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

: * women with primary breast cancer, without ongoing support for substance use. * An AUDIT-C score \>1 or more than one cigarette smoked per day. * Individuals able to consent to benefit of intervention focused on substance use. (Karnofsky Index \>70).

Exclusion criteria

: * Patients who currently use substances for which a second-line care is already committed. * Patients with a Karnofsky index \<70.

Design outcomes

Primary

MeasureTime frameDescription
Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months3 monthsIndividual decrease of 20% in the AUDIT (Alcohol Use Disorders Identification Test) score observed at 3 months AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 (no consumption) to 28 (alcohol dependence).
Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months3 months and 6 monthsIndividual decrease of 20% in the AUDIT score observed at 3 months compared to the value collected at baseline and maintained at 6 months. Success depends on tobacco consumption at 3 months and 6 months. AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 to 28. Its score ranges from 0 (no consumption) to 28 (alcohol dependence).

Secondary

MeasureTime frameDescription
Number of Patients Per Current Treatments at BaselineBaseline
Number of Patients Per Current Treatments at 3 Months3 months
Number of Patients Per Current Treatments at 6 Months6 months
Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 MonthsBaseline, 3 months and 6 monthsOngoing psychotropic treatment(s) at baseline, 3 months and 6 months.
Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional StateBaseline, 3 months and 6 monthsCurrent monitoring with regard to behaviour/emotional state
Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselineBaselineType of professional followed for behaviour/emotional state at baseline
Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months3 monthsType of professional followed for behaviour/emotional state at 3 months
Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months6 monthsType of professional followed for behaviour/emotional state at 6 months
AUDIT Score at Baseline, 3 Months, and 6 MonthsBaseline, 3 months, 6 monthsAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) score ranges from 0 (No alcohol consumption) to 12 (alcohol dependence). Consumption profiles can be derived from this. Higher scores indicate a worse outcome: alcohol dependence.
Currently, How Many Cigarettes Per Day do You Smoke on Average?Baseline, 3 months and 6 months
Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption3 monthsIndividual reduction of around 20% in the average daily consumption of alcohol and/or tobacco (calculated on the basis of consumption schedules) between inclusion and the first follow-up at 3 months (with no increase in the other consumption if the subject has both alcohol and tobacco consumption at inclusion).
Type of Consumption of Electronic CigarettesBaseline, 3 months and 6 months
Fagerström ScoreBaseline, 3 months, 6 monthsFagerström test assesses tobacco consumption and makes it possible to describe patterns of tobacco addiction. Its score ranges from 0 (non-addiction to smoking) to 10 (strong or very strong dependence on tobacco).
MADRS ScoreBaseline, 3 months, 6 monthsMADRS (Montgomery-Åsberg Depression Rating Scale) assesses the severity of depression in patients with mood disorders. Its score ranges from 0 (normothymic) to 60 (depression).
Score of HamiltonBaseline, 3 months and 6 monthsHamilton test assesses symptoms of anxiety. Its score ranges from 0 to 56. The higher the score is, the more severe the depression is.
Standardised Quality of Life Scores (EORTC - QLQ-C30)3 monthsQLQ-C30 questionnaire (EORTC) assesses quality of life across 15 dimensions : * 5 functional dimensions : Physical functioning, Role functioning, Emotional, Cognitive functioning, Social functioning; * 9 symptomatic dimensions: Fatigue, Nausea and vomiting, Pain, Dyspnea, Insomnia, Appetite loss, Diarrhoea, Financial difficulties; * 1 global health dimension: Global health status/QoL Each dimension is a standardised score ranges from 0 to 100. A low score corresponds to a low functional level, an absence of symptoms or a low level of QoL/ overall health and, conversely, so that a high score corresponds to a high functional level, a high presence of symptoms or a high level of QoL/overall health.
HEIQ ScoreBaseline, 3 months, 6 monthsHEIQ (Health Education Impact Questionnaire) assesses the concept of empowerment (health-promoting behaviours, commitment, social integration, etc.). Its scores range from 0 to 160. Higher scores mean a better health-related empowerment .
Motivation Score to Change Consumption Habits (Alcohol/Tobacco)Baseline, 3 months and 6 monthsThis score ranges from 0 to 140. The questionnaire consists of 14 questions on motivation to change alcohol/tobacco consumption habits, each with a response scale ranging from 0 (probably not) to 10 (probably). For each question, a sub-score ranges from 0 to 10 is given and then a total score of motivation to change consumption habits is calculated by adding up all the answers to the 14 items. The higher the score is, greater the patient's willingness to change his or her alcohol/tobacco consumption.
Satisfaction Questionnaire3 months
On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?3 monthsSatisfaction score ranges from 1 to 10. Low scores indicate less satisfaction.
Number of Patients Who Consume Electronic CigarettesBaseline, 3 months and 6 months
Number of Patients With Decreased Alcohol and/or Tobacco Consumption3 months and 6 monthsIndividual reduction of around 20% in the average daily consumption of alcohol and/or tobacco (calculated on the basis of consumption schedules) between inclusion and the first follow-up at 3 months and a continuation of this reduction at the second follow-up at 6 months (with no increase in the other consumption if the subject has both alcohol and tobacco consumption at inclusion). Success depends on alcohol and tobacco level consumption at 3 months and 6 months.

Countries

France

Participant flow

Participants by arm

ArmCount
Arm 1
Arm 1: Motivational Intervention group Motivational Intervention group: Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
51
Arm 2
Arm 2 : Educational advises group Educational advises group: Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
53
Total104

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyRefusal to continue34
Overall StudyWithdrawal by Subject93

Baseline characteristics

CharacteristicArm 2TotalArm 1
Age, Continuous48.0 years
STANDARD_DEVIATION 8.9
48.4 years
STANDARD_DEVIATION 9.6
48.8 years
STANDARD_DEVIATION 10.4
AUDIT Score (patient)2.9 scores on a scale
STANDARD_DEVIATION 2
3.2 scores on a scale
STANDARD_DEVIATION 3.3
3.4 scores on a scale
STANDARD_DEVIATION 4.2
Current family situation
Divorced
5 Participants12 Participants7 Participants
Current family situation
In a couple
16 Participants32 Participants16 Participants
Current family situation
Married
25 Participants46 Participants21 Participants
Current family situation
Single
6 Participants10 Participants4 Participants
Current family situation
Widowed
1 Participants4 Participants3 Participants
Currently, how many cigarettes per day does the patient's spouse smoke on average?10.8 Cigarettes
STANDARD_DEVIATION 6.9
11.1 Cigarettes
STANDARD_DEVIATION 7.5
11.5 Cigarettes
STANDARD_DEVIATION 8.1
Currently, how many cigarettes per day do you smoke on average?10.8 Cigarettes per day
STANDARD_DEVIATION 6.9
11.1 Cigarettes per day
STANDARD_DEVIATION 7.5
11.5 Cigarettes per day
STANDARD_DEVIATION 8.1
Current monitoring with regard to behaviour/emotional state
Missing
1 Participants1 Participants0 Participants
Current monitoring with regard to behaviour/emotional state
No
36 Participants74 Participants38 Participants
Current monitoring with regard to behaviour/emotional state
Yes
16 Participants29 Participants13 Participants
DSM5 - Current Life - Substance-related or addictive disorders
Alcohol
No
15 Participants34 Participants19 Participants
DSM5 - Current Life - Substance-related or addictive disorders
Alcohol
Yes
1 Participants4 Participants3 Participants
DSM5 - Current Life - Substance-related or addictive disorders
Cannabis
No
16 Participants37 Participants21 Participants
DSM5 - Current Life - Substance-related or addictive disorders
Cannabis
Yes
0 Participants1 Participants1 Participants
DSM5 - Current Life - Substance-related or addictive disorders
Other
No
16 Participants38 Participants22 Participants
DSM5 - Current Life - Substance-related or addictive disorders
Other
Yes
0 Participants0 Participants0 Participants
DSM5 - Current Life - Substance-related or addictive disorders
Tobacco
No
1 Participants5 Participants4 Participants
DSM5 - Current Life - Substance-related or addictive disorders
Tobacco
Yes
15 Participants33 Participants18 Participants
DSM5 - Substance-related or addictive disorders (current life)
No
37 Participants66 Participants29 Participants
DSM5 - Substance-related or addictive disorders (current life)
Yes
16 Participants38 Participants22 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Anxiety disorders
Missing
0 Participants0 Participants0 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Anxiety disorders
No
43 Participants88 Participants45 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Anxiety disorders
Yes
10 Participants16 Participants6 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Bipolar and related disorders
Missing
0 Participants0 Participants0 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Bipolar and related disorders
No
51 Participants102 Participants51 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Bipolar and related disorders
Yes
2 Participants2 Participants0 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Depressive disorders
Missing
0 Participants0 Participants0 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Depressive disorders
No
48 Participants95 Participants47 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Depressive disorders
Yes
5 Participants9 Participants4 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Disorders related to trauma or stressors
Missing
0 Participants1 Participants1 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Disorders related to trauma or stressors
No
50 Participants97 Participants47 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
Disorders related to trauma or stressors
Yes
3 Participants6 Participants3 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
OCD and related
Missing
0 Participants1 Participants1 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
OCD and related
No
52 Participants102 Participants50 Participants
DSM5 - Substance-related or addictive disorders (Current Life)
OCD and related
Yes
1 Participants1 Participants0 Participants
DSM5 - Substance-related or addictive disorders (whole life)
Alcohol
No
34 Participants70 Participants36 Participants
DSM5 - Substance-related or addictive disorders (whole life)
Alcohol
Yes
0 Participants4 Participants4 Participants
DSM5 - Substance-related or addictive disorders (whole life)
Cannabis
No
34 Participants73 Participants39 Participants
DSM5 - Substance-related or addictive disorders (whole life)
Cannabis
Yes
0 Participants1 Participants1 Participants
DSM5 - Substance-related or addictive disorders (whole life)
Other
No
34 Participants73 Participants39 Participants
DSM5 - Substance-related or addictive disorders (whole life)
Other
Yes
0 Participants1 Participants1 Participants
DSM5 - Substance-related or addictive disorders (whole life)
Tobacco
No
0 Participants5 Participants5 Participants
DSM5 - Substance-related or addictive disorders (whole life)
Tobacco
Yes
34 Participants69 Participants35 Participants
DSM5 - Substance-related or addictive disorders (whole life)
No
19 Participants30 Participants11 Participants
DSM5 - Substance-related or addictive disorders (whole life)
Yes
34 Participants74 Participants40 Participants
DSM5 - Whole Life
Anxiety disorders
No
39 Participants77 Participants38 Participants
DSM5 - Whole Life
Anxiety disorders
Yes
14 Participants27 Participants13 Participants
DSM5 - Whole Life
Bipolar and related disorders
No
51 Participants102 Participants51 Participants
DSM5 - Whole Life
Bipolar and related disorders
Yes
2 Participants2 Participants0 Participants
DSM5 - Whole Life
Depressive disorders
No
28 Participants63 Participants35 Participants
DSM5 - Whole Life
Depressive disorders
Yes
25 Participants41 Participants16 Participants
DSM5 - Whole Life
Disorders related to trauma or stressors
No
40 Participants80 Participants40 Participants
DSM5 - Whole Life
Disorders related to trauma or stressors
Yes
13 Participants24 Participants11 Participants
DSM5 - Whole Life
OCD and related
No
51 Participants101 Participants50 Participants
DSM5 - Whole Life
OCD and related
Yes
2 Participants3 Participants1 Participants
DSM5 - Whole Life
Substance-related or Addictive
No
19 Participants30 Participants11 Participants
DSM5 - Whole Life
Substance-related or Addictive
Yes
34 Participants74 Participants40 Participants
Electronic cigarettes
No
24 Participants49 Participants25 Participants
Electronic cigarettes
Yes
3 Participants5 Participants2 Participants
Fagerström score3.4 scores on a scale
STANDARD_DEVIATION 2.6
3.4 scores on a scale
STANDARD_DEVIATION 2.6
3.4 scores on a scale
STANDARD_DEVIATION 2.6
HEIQ (health Education Impact Questionnaire) score118.6 scores on a scale
STANDARD_DEVIATION 12.6
118.6 scores on a scale
STANDARD_DEVIATION 12.1
118.6 scores on a scale
STANDARD_DEVIATION 11.7
In the past year, how often did the patient's spouse smoke?
At least once a week
1 Participants4 Participants3 Participants
In the past year, how often did the patient's spouse smoke?
Every day or almost every day
17 Participants33 Participants16 Participants
In the past year, how often did the patient's spouse smoke?
Never
24 Participants44 Participants20 Participants
Level of education
Below high school diploma
10 Participants20 Participants10 Participants
Level of education
Higher than bachelor's degree
18 Participants35 Participants17 Participants
Level of education
High school diploma to bachelor's degree (included)
24 Participants46 Participants22 Participants
Level of education
No diploma
1 Participants3 Participants2 Participants
MADRS Score (Categorical variable)
Depression Medium
4 Participants10 Participants6 Participants
MADRS Score (Categorical variable)
Mild depression
21 Participants36 Participants15 Participants
MADRS Score (Categorical variable)
Normothymic
28 Participants58 Participants30 Participants
MADRS Score (Quantitative variable)7.9 scores on a scale
STANDARD_DEVIATION 6.3
7.9 scores on a scale
STANDARD_DEVIATION 6.9
7.9 scores on a scale
STANDARD_DEVIATION 7.6
Number of children1.8 Child
STANDARD_DEVIATION 1
1.8 Child
STANDARD_DEVIATION 1
1.8 Child
STANDARD_DEVIATION 0.9
Ongoing psychotropic treatment(s)
No
35 Participants70 Participants35 Participants
Ongoing psychotropic treatment(s)
Yes
18 Participants34 Participants16 Participants
Past treatment(s)
Chemotherapy
No
27 Participants49 Participants22 Participants
Past treatment(s)
Chemotherapy
Yes
26 Participants55 Participants29 Participants
Past treatment(s)
Hormonotherapy
No
51 Participants98 Participants47 Participants
Past treatment(s)
Hormonotherapy
Yes
2 Participants6 Participants4 Participants
Past treatment(s)
Radiotherapy
No
50 Participants99 Participants49 Participants
Past treatment(s)
Radiotherapy
Yes
3 Participants5 Participants2 Participants
Past treatment(s)
Surgery
No
31 Participants67 Participants36 Participants
Past treatment(s)
Surgery
Yes
22 Participants37 Participants15 Participants
Past treatment(s)
Without treatment
No
38 Participants79 Participants41 Participants
Past treatment(s)
Without treatment
Yes
15 Participants25 Participants10 Participants
Profession
Artisans, merchants and company director
2 Participants2 Participants0 Participants
Profession
Company's exécutives and higher intellectual profession
16 Participants27 Participants11 Participants
Profession
Economically inactive
6 Participants15 Participants9 Participants
Profession
Employees
25 Participants46 Participants21 Participants
Profession
Farmer-operators
0 Participants0 Participants0 Participants
Profession
Intermediate professions
1 Participants6 Participants5 Participants
Profession
Labor
2 Participants4 Participants2 Participants
Profession
Pensioners
1 Participants4 Participants3 Participants
Race and Ethnicity Not Collected0 Participants
Score Audit categorical variable (Patient)
Harmful consumption
6 Participants9 Participants3 Participants
Score Audit categorical variable (Patient)
Low-risk consumption
44 Participants77 Participants33 Participants
Score Audit categorical variable (Patient)
No consumption
3 Participants14 Participants11 Participants
Score Audit categorical variable (Patient)
Probable dependency
0 Participants4 Participants4 Participants
Score of Hamilton5.6 scores on a scale
STANDARD_DEVIATION 7
5.6 scores on a scale
STANDARD_DEVIATION 6.5
5.6 scores on a scale
STANDARD_DEVIATION 6.1
Sex: Female, Male
Female
53 Participants104 Participants51 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants
Spouse's AUDIT-C score3.4 scores on a scale
STANDARD_DEVIATION 1.9
3.5 scores on a scale
STANDARD_DEVIATION 2.2
3.6 scores on a scale
STANDARD_DEVIATION 2.6
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Appetite loss
17.0 Standardized scores on a scale16.2 Standardized scores on a scale15.3 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Cognitive functioning
77.8 Standardized scores on a scale78.8 Standardized scores on a scale79.9 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Constipation
15.7 Standardized scores on a scale15.0 Standardized scores on a scale14.3 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Diarrhoea
18.3 Standardized scores on a scale14.3 Standardized scores on a scale10.2 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Dyspnoea
20.9 Standardized scores on a scale22.7 Standardized scores on a scale24.5 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Emotional functioning
76.5 Standardized scores on a scale75.7 Standardized scores on a scale74.9 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Fatigue
42 Standardized scores on a scale43.7 Standardized scores on a scale45.4 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Financial difficulties
25.5 Standardized scores on a scale23.2 Standardized scores on a scale20.8 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Global health status/QoL (revised)
65.4 Standardized scores on a scale63.6 Standardized scores on a scale61.6 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Insomnia
34.0 Standardized scores on a scale33.7 Standardized scores on a scale33.3 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Nausea and vomiting
7.8 Standardized scores on a scale8.2 Standardized scores on a scale8.5 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Pain
23.9 Standardized scores on a scale25.3 Standardized scores on a scale26.9 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Physical functioning
83.5 Standardized scores on a scale82.2 Standardized scores on a scale80.8 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Role functioning
80.1 Standardized scores on a scale80.7 Standardized scores on a scale81.3 Standardized scores on a scale
Standardised Quality of Life Scores (EORTC - QLQ-C30)
Social functioning
74.8 Standardized scores on a scale75.5 Standardized scores on a scale76.2 Standardized scores on a scale
Tumor extension stage
Missing
3 Participants7 Participants4 Participants
Tumor extension stage
T0
2 Participants3 Participants1 Participants
Tumor extension stage
T1
11 Participants20 Participants9 Participants
Tumor extension stage
T2
21 Participants44 Participants23 Participants
Tumor extension stage
T3
13 Participants26 Participants13 Participants
Tumor extension stage
T4
3 Participants4 Participants1 Participants
Type of cancer
Canal carcinoma in situ
4 Participants4 Participants0 Participants
Type of cancer
Ductal carcinoma infiltrant
42 Participants90 Participants48 Participants
Type of cancer
Other
7 Participants10 Participants3 Participants
Type of consumption of electronic cigarettes
With nicotine
3 Participants4 Participants1 Participants
Type of consumption of electronic cigarettes
Without nicotine
0 Participants1 Participants1 Participants
Type of professional
Health professional specialising in tobaccoology and addiction
No
15 Participants28 Participants13 Participants
Type of professional
Health professional specialising in tobaccoology and addiction
Yes
1 Participants1 Participants0 Participants
Type of professional
Other professional
No
16 Participants28 Participants12 Participants
Type of professional
Other professional
Yes
0 Participants1 Participants1 Participants
Type of professional
Psychiatrist
No
14 Participants25 Participants11 Participants
Type of professional
Psychiatrist
Yes
2 Participants4 Participants2 Participants
Type of professional
Psychologist
No
3 Participants6 Participants3 Participants
Type of professional
Psychologist
Yes
13 Participants23 Participants10 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 00 / 0
other
Total, other adverse events
0 / 00 / 0
serious
Total, serious adverse events
0 / 00 / 0

Outcome results

Primary

Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months

Individual decrease of 20% in the AUDIT (Alcohol Use Disorders Identification Test) score observed at 3 months AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 (no consumption) to 28 (alcohol dependence).

Time frame: 3 months

Population: Only patients with available data at 3 months

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients With Individual Decrease of Tobacco Consumption at 3 MonthsSuccess23 Participants
Arm 1Number of Patients With Individual Decrease of Tobacco Consumption at 3 MonthsSuccess not maintained18 Participants
Arm 1Number of Patients With Individual Decrease of Tobacco Consumption at 3 MonthsMissing7 Participants
Arm 2Number of Patients With Individual Decrease of Tobacco Consumption at 3 MonthsSuccess19 Participants
Arm 2Number of Patients With Individual Decrease of Tobacco Consumption at 3 MonthsSuccess not maintained29 Participants
Arm 2Number of Patients With Individual Decrease of Tobacco Consumption at 3 MonthsMissing5 Participants
Primary

Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months

Individual decrease of 20% in the AUDIT score observed at 3 months compared to the value collected at baseline and maintained at 6 months. Success depends on tobacco consumption at 3 months and 6 months. AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 to 28. Its score ranges from 0 (no consumption) to 28 (alcohol dependence).

Time frame: 3 months and 6 months

Population: Only patients with available data at 3 months and 6 months

ArmMeasureGroupValue (NUMBER)
Arm 1Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 MonthsSuccess not maintained1 participants
Arm 1Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 MonthsSuccess17 participants
Arm 1Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 MonthsMissing5 participants
Arm 2Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 MonthsSuccess14 participants
Arm 2Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 MonthsSuccess not maintained1 participants
Arm 2Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 MonthsMissing4 participants
Secondary

AUDIT Score at Baseline, 3 Months, and 6 Months

Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score ranges from 0 (No alcohol consumption) to 12 (alcohol dependence). Consumption profiles can be derived from this. Higher scores indicate a worse outcome: alcohol dependence.

Time frame: Baseline, 3 months, 6 months

ArmMeasureGroupValue (MEAN)Dispersion
Arm 1AUDIT Score at Baseline, 3 Months, and 6 MonthsBaseline3.4 score on a scaleStandard Deviation 4.2
Arm 1AUDIT Score at Baseline, 3 Months, and 6 Months3 months3.6 score on a scaleStandard Deviation 5.4
Arm 1AUDIT Score at Baseline, 3 Months, and 6 Months6 months3.0 score on a scaleStandard Deviation 4.9
Arm 2AUDIT Score at Baseline, 3 Months, and 6 MonthsBaseline2.9 score on a scaleStandard Deviation 2
Arm 2AUDIT Score at Baseline, 3 Months, and 6 Months3 months2.6 score on a scaleStandard Deviation 1.8
Arm 2AUDIT Score at Baseline, 3 Months, and 6 Months6 months2.7 score on a scaleStandard Deviation 2.6
Secondary

Currently, How Many Cigarettes Per Day do You Smoke on Average?

Time frame: Baseline, 3 months and 6 months

Population: Only smokers who have completed form at baseline, 3 months and 6 months.

ArmMeasureGroupValue (MEAN)Dispersion
Arm 1Currently, How Many Cigarettes Per Day do You Smoke on Average?Baseline11.5 Cigarettes per dayStandard Deviation 8.1
Arm 1Currently, How Many Cigarettes Per Day do You Smoke on Average?3 months9.3 Cigarettes per dayStandard Deviation 6.1
Arm 1Currently, How Many Cigarettes Per Day do You Smoke on Average?6 months9.1 Cigarettes per dayStandard Deviation 6.9
Arm 2Currently, How Many Cigarettes Per Day do You Smoke on Average?Baseline10.8 Cigarettes per dayStandard Deviation 6.9
Arm 2Currently, How Many Cigarettes Per Day do You Smoke on Average?3 months10.4 Cigarettes per dayStandard Deviation 7
Arm 2Currently, How Many Cigarettes Per Day do You Smoke on Average?6 months11.0 Cigarettes per dayStandard Deviation 8.7
Secondary

Fagerström Score

Fagerström test assesses tobacco consumption and makes it possible to describe patterns of tobacco addiction. Its score ranges from 0 (non-addiction to smoking) to 10 (strong or very strong dependence on tobacco).

Time frame: Baseline, 3 months, 6 months

Population: In smokers only (N=54 smokers at baseline)

ArmMeasureGroupValue (MEAN)Dispersion
Arm 1Fagerström ScoreBaseline3.4 score on a scaleStandard Error 2.6
Arm 1Fagerström Score6 months3.0 score on a scaleStandard Error 2.3
Arm 1Fagerström Score3 months3.7 score on a scaleStandard Error 2.5
Arm 2Fagerström Score6 months3.7 score on a scaleStandard Error 2.7
Arm 2Fagerström ScoreBaseline3.4 score on a scaleStandard Error 2.6
Arm 2Fagerström Score3 months3.8 score on a scaleStandard Error 2.1
Secondary

HEIQ Score

HEIQ (Health Education Impact Questionnaire) assesses the concept of empowerment (health-promoting behaviours, commitment, social integration, etc.). Its scores range from 0 to 160. Higher scores mean a better health-related empowerment .

Time frame: Baseline, 3 months, 6 months

Population: Patients with available score at baseline or 3 months or 6 months.

ArmMeasureGroupValue (MEDIAN)Dispersion
Arm 1HEIQ ScoreBaseline119 scores on a scaleStandard Deviation 11.7
Arm 1HEIQ Score3 months114 scores on a scaleStandard Deviation 11.2
Arm 1HEIQ Score6 months118 scores on a scaleStandard Deviation 13.4
Arm 2HEIQ ScoreBaseline119 scores on a scaleStandard Deviation 12.6
Arm 2HEIQ Score3 months117.5 scores on a scaleStandard Deviation 12.5
Arm 2HEIQ Score6 months120 scores on a scaleStandard Deviation 12.5
Secondary

MADRS Score

MADRS (Montgomery-Åsberg Depression Rating Scale) assesses the severity of depression in patients with mood disorders. Its score ranges from 0 (normothymic) to 60 (depression).

Time frame: Baseline, 3 months, 6 months

Population: Eligible and assessable patients who have completed the MADRS questionnaire at baseline, 3 months and 6 months. For this questionnaire, there were no missing data at each time point (baseline, 3 months and 6 months).

ArmMeasureGroupValue (MEAN)Dispersion
Arm 1MADRS ScoreBaseline7.9 score on a scaleStandard Error 7.6
Arm 1MADRS Score3 months8.5 score on a scaleStandard Error 7.2
Arm 1MADRS Score6 months7.9 score on a scaleStandard Error 7.9
Arm 2MADRS ScoreBaseline7.9 score on a scaleStandard Error 6.3
Arm 2MADRS Score3 months6.3 score on a scaleStandard Error 5.8
Arm 2MADRS Score6 months4.8 score on a scaleStandard Error 5.2
Secondary

Motivation Score to Change Consumption Habits (Alcohol/Tobacco)

This score ranges from 0 to 140. The questionnaire consists of 14 questions on motivation to change alcohol/tobacco consumption habits, each with a response scale ranging from 0 (probably not) to 10 (probably). For each question, a sub-score ranges from 0 to 10 is given and then a total score of motivation to change consumption habits is calculated by adding up all the answers to the 14 items. The higher the score is, greater the patient's willingness to change his or her alcohol/tobacco consumption.

Time frame: Baseline, 3 months and 6 months

Population: Patients with available score.

ArmMeasureGroupValue (MEDIAN)Dispersion
Arm 1Motivation Score to Change Consumption Habits (Alcohol/Tobacco)6 months120 scores on a scaleStandard Deviation 19.6
Arm 1Motivation Score to Change Consumption Habits (Alcohol/Tobacco)Baseline121 scores on a scaleStandard Deviation 22.9
Arm 1Motivation Score to Change Consumption Habits (Alcohol/Tobacco)3 months129 scores on a scaleStandard Deviation 29
Arm 2Motivation Score to Change Consumption Habits (Alcohol/Tobacco)3 months126 scores on a scaleStandard Deviation 38.5
Arm 2Motivation Score to Change Consumption Habits (Alcohol/Tobacco)6 months126 scores on a scaleStandard Deviation 31.7
Arm 2Motivation Score to Change Consumption Habits (Alcohol/Tobacco)Baseline117.5 scores on a scaleStandard Deviation 32
Secondary

Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months

Type of professional followed for behaviour/emotional state at 6 months

Time frame: 6 months

Population: Patients with current monitoring with regard to behaviour/emotional state

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsPsychiatristNo5 Participants
Arm 1Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsPsychiatristYes3 Participants
Arm 1Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsHealth professional specialising in tobaccoology and addictionNo7 Participants
Arm 1Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsHealth professional specialising in tobaccoology and addictionYes1 Participants
Arm 1Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsOther professionalNo8 Participants
Arm 1Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsOther professionalYes0 Participants
Arm 1Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsPsychologistNo1 Participants
Arm 1Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsPsychologistYes7 Participants
Arm 2Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsPsychologistYes3 Participants
Arm 2Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsPsychiatristNo2 Participants
Arm 2Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsOther professionalNo6 Participants
Arm 2Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsPsychiatristYes4 Participants
Arm 2Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsPsychologistNo3 Participants
Arm 2Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsHealth professional specialising in tobaccoology and addictionNo6 Participants
Arm 2Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsOther professionalYes0 Participants
Arm 2Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 MonthsHealth professional specialising in tobaccoology and addictionYes0 Participants
Secondary

Number of Patients Per Current Treatments at 3 Months

Time frame: 3 months

Population: Only patients with available data at 3 months

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients Per Current Treatments at 3 MonthsChemotherapyNo32 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsNo treatmentMissing5 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsRadiotherapyYes10 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsNo treatmentNo36 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsRadiotherapyMissing5 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsNo treatmentYes10 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsHormonotherapyMissing5 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsSurgeryMissing5 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsChemotherapyYes14 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsSurgeryNo40 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsHormonotherapyNo33 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsSurgeryYes6 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsRadiotherapyNo36 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsChemotherapyMissing5 Participants
Arm 1Number of Patients Per Current Treatments at 3 MonthsHormonotherapyYes13 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsChemotherapyMissing4 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsChemotherapyNo40 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsChemotherapyYes9 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsRadiotherapyMissing4 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsRadiotherapyNo30 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsRadiotherapyYes19 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsHormonotherapyMissing4 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsHormonotherapyNo39 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsHormonotherapyYes10 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsNo treatmentMissing4 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsNo treatmentNo36 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsNo treatmentYes13 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsSurgeryMissing4 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsSurgeryNo47 Participants
Arm 2Number of Patients Per Current Treatments at 3 MonthsSurgeryYes2 Participants
Secondary

Number of Patients Per Current Treatments at 6 Months

Time frame: 6 months

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients Per Current Treatments at 6 MonthsChemotherapyNo46 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsRadiotherapyYes7 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsSurgeryNo49 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsChemotherapyYes5 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsHormonotherapyNo35 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsChemotherapyMissing0 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsHormonotherapyYes16 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsRadiotherapyMissing0 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsNo treatmentMissing0 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsNo treatmentNo42 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsSurgeryYes2 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsNo treatmentYes9 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsRadiotherapyNo44 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsHormonotherapyMissing0 Participants
Arm 1Number of Patients Per Current Treatments at 6 MonthsSurgeryMissing0 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsNo treatmentMissing0 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsSurgeryMissing0 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsSurgeryNo53 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsSurgeryYes0 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsChemotherapyMissing0 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsChemotherapyNo47 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsChemotherapyYes6 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsRadiotherapyMissing0 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsRadiotherapyNo45 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsRadiotherapyYes8 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsHormonotherapyMissing0 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsHormonotherapyNo28 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsHormonotherapyYes25 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsNo treatmentNo43 Participants
Arm 2Number of Patients Per Current Treatments at 6 MonthsNo treatmentYes10 Participants
Secondary

Number of Patients Per Current Treatments at Baseline

Time frame: Baseline

Population: Only patients with available data at baseline

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients Per Current Treatments at BaselineHormonotherapyYes2 Participants
Arm 1Number of Patients Per Current Treatments at BaselineNo treatmentMissing0 Participants
Arm 1Number of Patients Per Current Treatments at BaselineNo treatmentNo51 Participants
Arm 1Number of Patients Per Current Treatments at BaselineSurgeryMissing0 Participants
Arm 1Number of Patients Per Current Treatments at BaselineSurgeryNo50 Participants
Arm 1Number of Patients Per Current Treatments at BaselineSurgeryYes1 Participants
Arm 1Number of Patients Per Current Treatments at BaselineChemotherapyMissing0 Participants
Arm 1Number of Patients Per Current Treatments at BaselineChemotherapyNo4 Participants
Arm 1Number of Patients Per Current Treatments at BaselineChemotherapyYes47 Participants
Arm 1Number of Patients Per Current Treatments at BaselineRadiotherapyMissing0 Participants
Arm 1Number of Patients Per Current Treatments at BaselineRadiotherapyNo50 Participants
Arm 1Number of Patients Per Current Treatments at BaselineRadiotherapyYes1 Participants
Arm 1Number of Patients Per Current Treatments at BaselineHormonotherapyMissing0 Participants
Arm 1Number of Patients Per Current Treatments at BaselineHormonotherapyNo49 Participants
Arm 1Number of Patients Per Current Treatments at BaselineNo treatmentYes0 Participants
Arm 2Number of Patients Per Current Treatments at BaselineNo treatmentYes1 Participants
Arm 2Number of Patients Per Current Treatments at BaselineHormonotherapyYes1 Participants
Arm 2Number of Patients Per Current Treatments at BaselineChemotherapyNo2 Participants
Arm 2Number of Patients Per Current Treatments at BaselineNo treatmentMissing0 Participants
Arm 2Number of Patients Per Current Treatments at BaselineRadiotherapyYes0 Participants
Arm 2Number of Patients Per Current Treatments at BaselineNo treatmentNo52 Participants
Arm 2Number of Patients Per Current Treatments at BaselineChemotherapyYes51 Participants
Arm 2Number of Patients Per Current Treatments at BaselineHormonotherapyNo52 Participants
Arm 2Number of Patients Per Current Treatments at BaselineSurgeryMissing0 Participants
Arm 2Number of Patients Per Current Treatments at BaselineRadiotherapyMissing0 Participants
Arm 2Number of Patients Per Current Treatments at BaselineSurgeryNo52 Participants
Arm 2Number of Patients Per Current Treatments at BaselineHormonotherapyMissing0 Participants
Arm 2Number of Patients Per Current Treatments at BaselineSurgeryYes1 Participants
Arm 2Number of Patients Per Current Treatments at BaselineRadiotherapyNo53 Participants
Arm 2Number of Patients Per Current Treatments at BaselineChemotherapyMissing0 Participants
Secondary

Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months

Type of professional followed for behaviour/emotional state at 3 months

Time frame: 3 months

Population: Patients with current monitoring with regard to behaviour/emotional state

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsPsychiatristNo13 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsPsychiatristYes2 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsPsychologistNo4 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsPsychologistYes11 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsHealth professional specialising in tobaccoology and addictionNo15 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsHealth professional specialising in tobaccoology and addictionYes0 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsOther professionalNo13 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsOther professionalYes2 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsOther professionalYes0 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsPsychiatristNo5 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsHealth professional specialising in tobaccoology and addictionNo8 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsOther professionalNo8 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsPsychologistNo3 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsHealth professional specialising in tobaccoology and addictionYes0 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsPsychologistYes5 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 MonthsPsychiatristYes3 Participants
Secondary

Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline

Type of professional followed for behaviour/emotional state at baseline

Time frame: Baseline

Population: Patients with current monitoring with regard to behaviour/emotional state

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselineOther professionalNo12 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselinePsychiatristYes2 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselinePsychologistYes10 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselineHealth professional specialising in tobaccoology and addictionNo13 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselinePsychologistNo3 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselinePsychiatristNo11 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselineOther professionalYes1 Participants
Arm 1Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselineHealth professional specialising in tobaccoology and addictionYes0 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselineOther professionalYes0 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselineHealth professional specialising in tobaccoology and addictionYes1 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselinePsychologistNo3 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselinePsychologistYes13 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselinePsychiatristNo14 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselinePsychiatristYes2 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselineHealth professional specialising in tobaccoology and addictionNo15 Participants
Arm 2Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at BaselineOther professionalNo16 Participants
Secondary

Number of Patients Who Consume Electronic Cigarettes

Time frame: Baseline, 3 months and 6 months

Population: Only smokers at baseline (N=54), 3 months (N=37) and 6 months (N=30).

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients Who Consume Electronic CigarettesBaselineNo25 Participants
Arm 1Number of Patients Who Consume Electronic CigarettesBaselineYes2 Participants
Arm 1Number of Patients Who Consume Electronic Cigarettes3 monthsNo17 Participants
Arm 1Number of Patients Who Consume Electronic Cigarettes3 monthsYes3 Participants
Arm 1Number of Patients Who Consume Electronic Cigarettes6 monthsNo15 Participants
Arm 1Number of Patients Who Consume Electronic Cigarettes6 monthsYes2 Participants
Arm 2Number of Patients Who Consume Electronic Cigarettes6 monthsNo12 Participants
Arm 2Number of Patients Who Consume Electronic CigarettesBaselineNo24 Participants
Arm 2Number of Patients Who Consume Electronic Cigarettes3 monthsYes1 Participants
Arm 2Number of Patients Who Consume Electronic CigarettesBaselineYes3 Participants
Arm 2Number of Patients Who Consume Electronic Cigarettes6 monthsYes1 Participants
Arm 2Number of Patients Who Consume Electronic Cigarettes3 monthsNo16 Participants
Secondary

Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months

Ongoing psychotropic treatment(s) at baseline, 3 months and 6 months.

Time frame: Baseline, 3 months and 6 months

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months3 monthsMissing5 Participants
Arm 1Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months3 monthsNo34 Participants
Arm 1Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 MonthsBaselineYes16 Participants
Arm 1Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months3 monthsYes12 Participants
Arm 1Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months6 monthsNo29 Participants
Arm 1Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months6 monthsYes8 Participants
Arm 1Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 MonthsBaselineMissing0 Participants
Arm 1Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months6 monthsMissing14 Participants
Arm 1Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 MonthsBaselineNo35 Participants
Arm 2Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months6 monthsMissing9 Participants
Arm 2Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 MonthsBaselineNo35 Participants
Arm 2Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 MonthsBaselineYes18 Participants
Arm 2Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months3 monthsMissing4 Participants
Arm 2Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months6 monthsNo30 Participants
Arm 2Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 MonthsBaselineMissing0 Participants
Arm 2Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months3 monthsNo35 Participants
Arm 2Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months3 monthsYes14 Participants
Arm 2Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months6 monthsYes14 Participants
Secondary

Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State

Current monitoring with regard to behaviour/emotional state

Time frame: Baseline, 3 months and 6 months

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional StateBaselineMissing0 Participants
Arm 1Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State3 monthsYes15 Participants
Arm 1Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional StateBaselineNo38 Participants
Arm 1Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State3 monthsNo31 Participants
Arm 1Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional StateBaselineYes13 Participants
Arm 1Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State6 monthsNo29 Participants
Arm 1Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State6 monthsMissing14 Participants
Arm 1Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State6 monthsYes8 Participants
Arm 1Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State3 monthsMissing5 Participants
Arm 2Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State6 monthsYes6 Participants
Arm 2Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State3 monthsMissing4 Participants
Arm 2Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State3 monthsNo41 Participants
Arm 2Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State3 monthsYes8 Participants
Arm 2Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State6 monthsMissing10 Participants
Arm 2Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional StateBaselineMissing1 Participants
Arm 2Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional StateBaselineNo36 Participants
Arm 2Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State6 monthsNo37 Participants
Arm 2Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional StateBaselineYes16 Participants
Secondary

Number of Patients With Decreased Alcohol and/or Tobacco Consumption

Individual reduction of around 20% in the average daily consumption of alcohol and/or tobacco (calculated on the basis of consumption schedules) between inclusion and the first follow-up at 3 months and a continuation of this reduction at the second follow-up at 6 months (with no increase in the other consumption if the subject has both alcohol and tobacco consumption at inclusion). Success depends on alcohol and tobacco level consumption at 3 months and 6 months.

Time frame: 3 months and 6 months

Population: Patients with tobacco or alcohol consumption at baseline and data available at 3 months and 6 months

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients With Decreased Alcohol and/or Tobacco ConsumptionSuccess6 Participants
Arm 1Number of Patients With Decreased Alcohol and/or Tobacco ConsumptionFailure2 Participants
Arm 1Number of Patients With Decreased Alcohol and/or Tobacco ConsumptionMissing4 Participants
Arm 2Number of Patients With Decreased Alcohol and/or Tobacco ConsumptionSuccess6 Participants
Arm 2Number of Patients With Decreased Alcohol and/or Tobacco ConsumptionFailure2 Participants
Arm 2Number of Patients With Decreased Alcohol and/or Tobacco ConsumptionMissing7 Participants
Secondary

Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption

Individual reduction of around 20% in the average daily consumption of alcohol and/or tobacco (calculated on the basis of consumption schedules) between inclusion and the first follow-up at 3 months (with no increase in the other consumption if the subject has both alcohol and tobacco consumption at inclusion).

Time frame: 3 months

Population: Patients with tobacco or alcohol consumption at baseline and available data at 3 months

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Number of Patients With Individual Decreased of Alcohol and/or Tobacco ConsumptionSuccess12 Participants
Arm 1Number of Patients With Individual Decreased of Alcohol and/or Tobacco ConsumptionFailure22 Participants
Arm 1Number of Patients With Individual Decreased of Alcohol and/or Tobacco ConsumptionMissing14 Participants
Arm 2Number of Patients With Individual Decreased of Alcohol and/or Tobacco ConsumptionSuccess15 Participants
Arm 2Number of Patients With Individual Decreased of Alcohol and/or Tobacco ConsumptionFailure26 Participants
Arm 2Number of Patients With Individual Decreased of Alcohol and/or Tobacco ConsumptionMissing12 Participants
Secondary

On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?

Satisfaction score ranges from 1 to 10. Low scores indicate less satisfaction.

Time frame: 3 months

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?70 Participants
Arm 1On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?Missing15 Participants
Arm 1On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?811 Participants
Arm 1On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?53 Participants
Arm 1On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?98 Participants
Arm 1On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?62 Participants
Arm 1On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?1012 Participants
Arm 1On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?30 Participants
Arm 2On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?1011 Participants
Arm 2On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?Missing6 Participants
Arm 2On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?31 Participants
Arm 2On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?64 Participants
Arm 2On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?73 Participants
Arm 2On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?817 Participants
Arm 2On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?96 Participants
Arm 2On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?55 Participants
Secondary

Satisfaction Questionnaire

Time frame: 3 months

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Satisfaction QuestionnaireDo you think it would be important to ask cancer patients about their consumption behaviour?Missing14 Participants
Arm 1Satisfaction QuestionnaireDo you think it would be important to ask cancer patients about their consumption behaviour?No1 Participants
Arm 1Satisfaction QuestionnaireDo you think it would be important to ask cancer patients about their consumption behaviour?Yes30 Participants
Arm 1Satisfaction QuestionnaireDo you think it would be important to ask cancer patients about their consumption behaviour?Don't know6 Participants
Arm 1Satisfaction QuestionnaireWould it be useful to ask cancer patients about their alcohol/tobacco consumption behaviourMissing14 Participants
Arm 1Satisfaction QuestionnaireWould it be useful to ask cancer patients about their alcohol/tobacco consumption behaviourNo1 Participants
Arm 1Satisfaction QuestionnaireWould it be useful to ask cancer patients about their alcohol/tobacco consumption behaviourYes33 Participants
Arm 1Satisfaction QuestionnaireWould it be useful to ask cancer patients about their alcohol/tobacco consumption behaviourDon't know3 Participants
Arm 1Satisfaction QuestionnaireWould you have liked the questions on consumption to have been asked at another time?Missing16 Participants
Arm 1Satisfaction QuestionnaireWould you have liked the questions on consumption to have been asked at another time?No29 Participants
Arm 1Satisfaction QuestionnaireWould you have liked the questions on consumption to have been asked at another time?Yes6 Participants
Arm 1Satisfaction QuestionnaireWould you have liked the questions on consumption to have been asked at another time?Don't know0 Participants
Arm 2Satisfaction QuestionnaireWould you have liked the questions on consumption to have been asked at another time?Yes6 Participants
Arm 2Satisfaction QuestionnaireDo you think it would be important to ask cancer patients about their consumption behaviour?Missing6 Participants
Arm 2Satisfaction QuestionnaireWould it be useful to ask cancer patients about their alcohol/tobacco consumption behaviourYes40 Participants
Arm 2Satisfaction QuestionnaireDo you think it would be important to ask cancer patients about their consumption behaviour?No2 Participants
Arm 2Satisfaction QuestionnaireWould you have liked the questions on consumption to have been asked at another time?No41 Participants
Arm 2Satisfaction QuestionnaireDo you think it would be important to ask cancer patients about their consumption behaviour?Yes42 Participants
Arm 2Satisfaction QuestionnaireWould it be useful to ask cancer patients about their alcohol/tobacco consumption behaviourDon't know5 Participants
Arm 2Satisfaction QuestionnaireDo you think it would be important to ask cancer patients about their consumption behaviour?Don't know3 Participants
Arm 2Satisfaction QuestionnaireWould you have liked the questions on consumption to have been asked at another time?Don't know0 Participants
Arm 2Satisfaction QuestionnaireWould it be useful to ask cancer patients about their alcohol/tobacco consumption behaviourMissing7 Participants
Arm 2Satisfaction QuestionnaireWould you have liked the questions on consumption to have been asked at another time?Missing6 Participants
Arm 2Satisfaction QuestionnaireWould it be useful to ask cancer patients about their alcohol/tobacco consumption behaviourNo1 Participants
Secondary

Score of Hamilton

Hamilton test assesses symptoms of anxiety. Its score ranges from 0 to 56. The higher the score is, the more severe the depression is.

Time frame: Baseline, 3 months and 6 months

Population: Eligible and assessable patients who have completed the Hamilton questionnaire at baseline, 3 months and 6 months. For this questionnaire, there were no missing data at each time point (baseline, 3 months and 6 months).

ArmMeasureGroupValue (MEAN)Dispersion
Arm 1Score of HamiltonBaseline5.6 score on a scaleStandard Deviation 6.1
Arm 1Score of Hamilton3 months4.5 score on a scaleStandard Deviation 5.3
Arm 1Score of Hamilton6 months4.4 score on a scaleStandard Deviation 6
Arm 2Score of HamiltonBaseline5.6 score on a scaleStandard Deviation 7
Arm 2Score of Hamilton3 months3.5 score on a scaleStandard Deviation 4.1
Arm 2Score of Hamilton6 months2.6 score on a scaleStandard Deviation 3.3
Secondary

Standardised Quality of Life Scores (EORTC - QLQ-C30)

QLQ-C30 questionnaire (EORTC) assesses quality of life across 15 dimensions : * 5 functional dimensions : Physical functioning, Role functioning, Emotional, Cognitive functioning, Social functioning; * 9 symptomatic dimensions: Fatigue, Nausea and vomiting, Pain, Dyspnea, Insomnia, Appetite loss, Diarrhoea, Financial difficulties; * 1 global health dimension: Global health status/QoL Each dimension is a standardised score ranges from 0 to 100. A low score corresponds to a low functional level, an absence of symptoms or a low level of QoL/ overall health and, conversely, so that a high score corresponds to a high functional level, a high presence of symptoms or a high level of QoL/overall health.

Time frame: 3 months

Population: Participants who completed at least one item of the questionnaire. Note that some participants may not have completed the 30 items of the questionnaires, which explains why the number of participants differs for the different items of the questionnaires.

ArmMeasureGroupValue (MEAN)Dispersion
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Role functioning84.6 scores on a scaleStandard Deviation 18
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Emotional functioning67.9 scores on a scaleStandard Deviation 27
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Cognitive functioning75.8 scores on a scaleStandard Deviation 27.1
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Nausea and vomiting5.3 scores on a scaleStandard Deviation 12.6
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Financial difficulties23.8 scores on a scaleStandard Deviation 32.3
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Physical functioning81.0 scores on a scaleStandard Deviation 16.4
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Social functioning70.6 scores on a scaleStandard Deviation 29.9
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Fatigue42.0 scores on a scaleStandard Deviation 26.4
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Pain26.4 scores on a scaleStandard Deviation 25.3
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Dyspnoea15.4 scores on a scaleStandard Deviation 25.9
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Insomnia42.3 scores on a scaleStandard Deviation 32.5
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Appetite loss14.6 scores on a scaleStandard Deviation 22.4
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Constipation8.9 scores on a scaleStandard Deviation 18.3
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Diarrhoea4.9 scores on a scaleStandard Deviation 11.9
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Global health status/QoL61.1 scores on a scaleStandard Deviation 17.9
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Social functioning78.7 scores on a scaleStandard Deviation 24.3
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Role functioning89.0 scores on a scaleStandard Deviation 17.8
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Insomnia37.6 scores on a scaleStandard Deviation 30.8
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Fatigue39.0 scores on a scaleStandard Deviation 21.1
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Constipation5.7 scores on a scaleStandard Deviation 12.7
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Nausea and vomiting3.9 scores on a scaleStandard Deviation 7.9
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Dyspnoea27.0 scores on a scaleStandard Deviation 19.2
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Pain28.7 scores on a scaleStandard Deviation 21.3
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Financial difficulties21.3 scores on a scaleStandard Deviation 28.2
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Global health status/QoL64.2 scores on a scaleStandard Deviation 18.4
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Appetite loss12.1 scores on a scaleStandard Deviation 18.9
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Physical functioning82.1 scores on a scaleStandard Deviation 18.1
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Emotional functioning76.3 scores on a scaleStandard Deviation 20.2
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Cognitive functioning81.6 scores on a scaleStandard Deviation 18.5
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Diarrhoea8.0 scores on a scaleStandard Deviation 22.4
Secondary

Standardised Quality of Life Scores (EORTC - QLQ-C30)

QLQ-C30 questionnaire (EORTC) assesses quality of life across 15 dimensions : * 5 functional dimensions : Physical functioning, Role functioning, Emotional, Cognitive functioning, Social functioning; * 9 symptomatic dimensions: Fatigue, Nausea and vomiting, Pain, Dyspnea, Insomnia, Appetite loss, Diarrhoea, Financial difficulties; * 1 global health dimension: Global health status/QoL Each dimension is a standardised score ranges from 0 to 100. A low score corresponds to a low functional level, an absence of symptoms or a low level of QoL/ overall health and, conversely, so that a high score corresponds to a high functional level, a high presence of symptoms or a high level of QoL/overall health.

Time frame: 6 months

Population: Participants who completed at least one item of the questionnaire. Note that some participants may not have completed the 30 items of the questionnaires, which explains why the number of participants differs for the different items of the questionnaires.

ArmMeasureGroupValue (MEAN)Dispersion
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Cognitive functioning72.5 scores on a scaleStandard Deviation 30.2
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Pain27.0 scores on a scaleStandard Deviation 27
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Diarrhoea5.4 scores on a scaleStandard Deviation 18.4
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Dyspnoea17.1 scores on a scaleStandard Deviation 24.4
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Emotional functioning62.6 scores on a scaleStandard Deviation 28.7
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Insomnia48.6 scores on a scaleStandard Deviation 33
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Role functioning81.5 scores on a scaleStandard Deviation 24.1
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Appetite loss13.5 scores on a scaleStandard Deviation 24.2
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Fatigue44.1 scores on a scaleStandard Deviation 23.6
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Constipation20.7 scores on a scaleStandard Deviation 31.8
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Social functioning70.7 scores on a scaleStandard Deviation 33.4
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Financial difficulties23.1 scores on a scaleStandard Deviation 33.6
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Nausea and vomiting7.2 scores on a scaleStandard Deviation 20.6
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Global health status/QoL58.3 scores on a scaleStandard Deviation 20.7
Arm 1Standardised Quality of Life Scores (EORTC - QLQ-C30)Physical functioning80.2 scores on a scaleStandard Deviation 18.5
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Global health status/QoL63.6 scores on a scaleStandard Deviation 20.6
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Physical functioning86.0 scores on a scaleStandard Deviation 16
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Role functioning88.2 scores on a scaleStandard Deviation 19.5
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Emotional functioning75.6 scores on a scaleStandard Deviation 18.2
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Cognitive functioning78.5 scores on a scaleStandard Deviation 21.8
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Social functioning81.7 scores on a scaleStandard Deviation 27.6
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Diarrhoea7.5 scores on a scaleStandard Deviation 16
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Fatigue31.4 scores on a scaleStandard Deviation 20.5
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Nausea and vomiting4.1 scores on a scaleStandard Deviation 12.2
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Pain26.8 scores on a scaleStandard Deviation 25.8
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Dyspnoea21.1 scores on a scaleStandard Deviation 27.6
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Insomnia37.4 scores on a scaleStandard Deviation 32.7
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Appetite loss3.3 scores on a scaleStandard Deviation 10
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Constipation9.8 scores on a scaleStandard Deviation 22.7
Arm 2Standardised Quality of Life Scores (EORTC - QLQ-C30)Financial difficulties22.8 scores on a scaleStandard Deviation 35.3
Secondary

Type of Consumption of Electronic Cigarettes

Time frame: Baseline, 3 months and 6 months

Population: Patient with electronic cigarette use and who answered the form

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Arm 1Type of Consumption of Electronic Cigarettes6 monthsWith nicotine1 Participants
Arm 1Type of Consumption of Electronic Cigarettes6 monthsWithout nicotine1 Participants
Arm 1Type of Consumption of Electronic CigarettesBaselineWith nicotine1 Participants
Arm 1Type of Consumption of Electronic CigarettesBaselineWithout nicotine1 Participants
Arm 1Type of Consumption of Electronic Cigarettes3 monthsWith nicotine2 Participants
Arm 1Type of Consumption of Electronic Cigarettes3 monthsWithout nicotine1 Participants
Arm 2Type of Consumption of Electronic Cigarettes3 monthsWith nicotine1 Participants
Arm 2Type of Consumption of Electronic Cigarettes6 monthsWith nicotine1 Participants
Arm 2Type of Consumption of Electronic CigarettesBaselineWithout nicotine0 Participants
Arm 2Type of Consumption of Electronic Cigarettes6 monthsWithout nicotine0 Participants
Arm 2Type of Consumption of Electronic Cigarettes3 monthsWithout nicotine0 Participants
Arm 2Type of Consumption of Electronic CigarettesBaselineWith nicotine3 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026